Quantum mechanical studies of DNA and LNA

Nucleic Acid Therapeutics

Volumn 24, Issue 2, 2014, Pages 139-148

  Koch, Troels ^a   Shim, Irene ^b   Lindow, Morten ^a   Ørum, Henrik ^a   Bohr, Henrik G ^b  

^a Santaris Pharma AS   (Denmark)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DNA; LOCKED NUCLEIC ACID; MICRORNA; OLIGONUCLEOTIDE; PHOSPHOROTHIOIC ACID;

ARTICLE; CHEMICAL STRUCTURE; MOLECULAR INTERACTION; MOLECULE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE; QUANTUM MECHANICS; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; THREE DIMENSIONAL IMAGING;

DNA; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NUCLEIC ACID CONFORMATION; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; QUANTUM THEORY; STATIC ELECTRICITY; THERMODYNAMICS;

EID: 84896997531     PISSN: 21593337     EISSN: None     Source Type: Journal    
DOI: 10.1089/nat.2013.0465     Document Type: Article

References (74)

1. ABDALI, S., JALKANEN, K. J., BOHR, H., SUHAI, S., and NIEMINEN, R. M. (2002). The VA and VCD spectra of various isotopes of L-alanine in aqueous solution. Chem. Phys. 282, 219-235.
2. ALTMANN, K.-H., DEAN, N. M., FABBRO, D., FREIER, S. M., GEIGER, T., HÄ NER, R., HÜ SKEN, D., MARTIN, P., MONIA, B. P., MÜ LLER, M., et al. (1996). Second generation OD antisense oligonucleotides: from nuclease resistance to biological efficacy in animals. Chimia 50, 168-176.
3. BELTINGER, C., SARAGOVI, H. U., SMITH, R. M., LESAUTEUR, L., SHAH, N., DEDIONISIO, L., CHRISTENSEN, L., RAIBLE, A., JARETT, L., and GEWIRTZ, A. M. (1995). Binding, uptake, and intracellular trafficking of phosphorothioate- modified oligodeoxynucleotides. J. Clin. Invest 95, 1814-1823.
4. BOHR, H. G. (2013). Perspectives in quantum nanobiology and biophysical chemistry. Current Phys. Chem. 3, 4-8.
5. BURGOYNE, N. J., and JACKSON, R. M. (2006). Predicting protein interaction sites: binding hot-spots in protein-protein and protein-ligand interfaces. Bioinformatics 22, 1335-1342.
6. CHONG, L. T., DEMPSTER, S. E., HENDSCH, Z. S., LEE, L. P., and TIDOR, B. (1998). Computation of electrostatic complements to proteins: a case of charge stabilized binding. Protein Sci. 7, 206-210.
7. COHEN, J. S. (1993). Phosphorothioate oligonucleotides. In: Antisense Research and Applications. S. T. Crooke and B. Lebleu, eds. (CRC Press: Boca Raton, FL), pp. 205-223.
8. COOK, P. D. (1999). Making drugs out of oligonucleotides: a brief review and perspective. Nucleosides Nucleotides 18, 1141-1162.
9. COREY, D. R. (1997). Peptide nucleic acids: expanding the scope of recognition. TIBTECH 15, 224-229.
10. DANGLER, C. A. (1996). Nucleic Acid Analysis: Principles and Bioapplications. (Wiley-Liss: New York), pp. 1-475.
11. DAVIS, S., LOLLO, B., FREIER, S., and ESAU, C. (2006). Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res. 34, 2294-2304.
12. DEBART, F., ABES, S., DEGLANE, G., MOULTON, H. M., CLAIR, P., GAIT, M. J., VASSEUR, J. J., and LEBLEU, B. (2007). Chemical modifications to improve the cellular uptake of oligonucleotides. Curr. Top. Med. Chem. 7, 727-737.
13. DEMIDOV, V. V., and FRANK-KAMENETSKII, M. D. (2004). Two sides of the coin: affinity and specificity of nucleic acid interaction. Trends Biochem. Sci. 29, 62-71.
14. DHIMOY, R. K., BALANARAYAN, P., ANDSHRIDHAR, G. R. (2008). An appraisal of Poincaré-Hopf relation and application to topography of molecular electrostatic potentials. J. Chem. Phys. 129, 174103.
15. DHIMOY, R. K., BALANARAYAN, P., and SHRIDHAR, G. R. (2013). Signatures of molecular recognition from topography of electrostatic potential. J. Chem. Sci. 121, 815-821.
16. ECKSTEIN, F. (2007). The versatility of oligonucleotides as potential therapeutics. Expert. Opin. Biol. Ther. 7, 1021-1034.
17. ELMEN, J., LINDOW, M., SCHUTZ, S., LAWRENCE, M., PETRI, A., OBAD, S., LINDHOLM, M., HEDTJARN, M., HANSEN, H. F., BERGER, U., GULLANS, S., KEARNEY, P., SARNOW, P., STRAARUP, E. M., and KAUPPINEN, S. (2008a). LNA-mediated microRNA silencing in non-human primates. Nature 452, 896-899.
18. ELMEN, J., LINDOW, M., SILAHTAROGLU, A., BAK, M., CHRISTENSEN, M., LIND-THOMSEN, A., HEDTJARN, M., HANSEN, J. B., HANSEN, H. F., STRAARUP, E. M., MCCULLAGH, K., KEARNEY, P., and KAUPPINEN, S. (2008b). Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 36, 1153-1162.
19. FREIER, S. M., and ALTMANN, K.-H. (1997). The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes. Nucleic Acid Res. 25, 4429-4443.
20. FRISCH, M. J., TRUCKS, G. W.; SCHLEGEL, H. B.; SCUSERIA, G. E.; ROBB, M. A.; CHEESEMAN, J. R.; SCALMANI, G.; BARONE, V.; MENNUCCI, B.; PETERSSON, G. A., et al. (2009). Gaussian 09, (Gaussian, Inc., Wallingford CT)
21. HAGEDORN, P. H., YAKIMOV, V., OTTOSEN, S., KAMMLER, S., NIELSEN, N. F., HOG, A. M., HEDTJARN, M., MELDGAARD, M., MOLLER, M. R., ORUM, H., et al. (2013). Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern. Nucleic Acid Ther. 23, 302-310.
22. HANSEN, J. B., FISKER, N., WESTERGAARD, M., KJAERULFF, L. S., HANSEN, H. F., THRUE, C. A., ROSENBOHM, C., WISSENBACH, M., ORUM, H., and KOCH, T. (2008). SPC3042: a proapoptotic survivin inhibitor. Mol. Cancer Ther. 7, 2736-2745.
23. HANVEY, J. C., PEFFER, N. J., BISI, J. E., THOMSON, S. A., CADILLA, R., JOSEY, J. A., RICCA, D. J., HASSMAN, C. F., BONHAM, M. A., AU, K. G., et al. (1992). Antisense and antigene properties of peptide nucleic acid. Science 258, 1481-1485.
24. HARRIS, C. R., MACKOY, T., MACHADO C. D. ANA, XU, D., ROHS, R., and FENLEY, O. M. (2012). Opposite attract: shape and electrostatic complementarity in Protein-DNA Complexes. In: Innovations in Biomolecular Modeling and Simulations, Volume 2. T. Schlick, ed. (Royal Society of Chemistry), pp. 53-80.
25. HUGHESMANN, C. B., TURNER, R. F. B., and HAYNES C. A. (2011). Role of heat capacity change in understanding and modeling melting thermodynamics of complementary duplexes containing standard and nucleobase-modified LNA. Biochemistry 50, 5354-5368.
26. JALKANEN J. K, NIEMINEN M. R., FRIMAND K., BOHR J., BOHR H., WADE C. R., TAJKHORSHID E., and SUHAI S. (2001). A comparison of aqueous solvent models used in the calculation of the Raman and ROA spectra od L-alanine. Chem. Phys. 265, 125-151.
27. JEPSEN, J. S., and WENGEL, J. (2004). LNA-Antisense rivals siRNA for gene silencing. Curr. Opin. Drug Discov. Devel. 7:188-194.
28. KANGAS, E., and TIDOR, B. (1999). Charge optimization leads to favorable electrostatic binding free energy. Phys. Rev. E. Stat. Phys. Plasmas. Fluids Relat. Interdiscip. Topics 59, 5958-5961.
29. KENNY, P. W. (2009). Hydrogen bonding, electrostatic potential, and molecular design. J. Chem. Inf. Model. 49, 1234-1244.
30. KOCH, T. (2013). LNA antisense: a review. Curr. Phys. Chem. 3, 55-68.
31. KOCH, T., and ØRUM, H. (2007). Locked nucleic acid. In: Antisense Drug Discovery. S. T. Crooke, ed. (CRC Press: Boca Raton, FL), pp. 519-565.
32. KOCH, T., ROSENBOHM, C., HANSEN, H. F., F., HANSEN, B., STRAARUP, E. M., and KAUPPINEN, S. (2008). Locked nucleic acid: properties and therapeutic aspects. In: Therapeutic Oligonucleotides. Jens Kurreck, ed. (RSC Publishing: Cambridge, UK), pp. 103-141.
33. KOLLER, E., VINCENT, T. M., CHAPPELL, A., DE, S., MANOHARAN, M., and BENNETT, C. F. (2011). Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res. 39, 4795-4807.
34. KRAUT, D. A., SIGALA, P. A., PYBUS, B., LIU, C. W., RINGE, D., PETSKO, G. A., and HERSCHLAG, D. (2006). Testing electrostatic complementarity in enzyme catalysis: hydrogen bonding in the ketosteroid isomerase oxyanion hole. PLoS Biol. 4, e99.
35. KRUTZFELDT, J., RAJEWSKY, N., BRAICH, R., RAJEEV, K. G., TUSCHL, T., MANOHARAN, M., and STOFFEL, M. (2005). Silencing of microRNAs in vivo with 'antagomirs'. Nature 438, 685-689.
36. LAI, J. C., BROWN, B. D., VOSKRESENSKIY, A. M., VONHOFF, S., KLUSSMAN, S., TAN, W., COLOMBINI, M., WEERATNA, R., MILLER, P., BENIMETSKAYA, L., and STEIN, C. A. (2007A). Comparison of d-g3139 and its enantiomer L-g3139 in melanoma cells demonstrates minimal in vitro but dramatic in vivo chiral dependency. Mol. Ther. 15, 270-278.
37. LANFORD, R., HILDEBRANDT-ERIKSEN, E. S., PETRI, A., PERSSON, R., LINDOW, M., MUNK, M. E., KAUPPINEN, S., and ØRUM, H. (2010). Therapeutic silencing of micro-RNA-122 in Primates with chronic hepatitis C virus infection. Science 327, 198-201.
38. LAXTON, C., BRADY, K., MOSCHOS, S., TURNPENNY, P., RAWAL, J., PRYDE, D. C., SIDDERS, B., CORBAU, R., PICKFORD, C., and MURRAY, E. J. (2011). Selection, optimization, and pharmacokinetic properties of a novel, potent antiviral locked nucleic acid-based antisense oligomer targeting hepatitis C virus internal ribosome entry site. Antimicrob. Agents Chemother. 55, 3105-3114.
39. LEBEDEVA, I., BENIMETSKAYA, L., STEIN, C. A., and VILENCHIK, M. (2000). Cellular delivery of antisense oligonucleotides. Eur. J. Pharm. Biopharm. 50, 101-119.
40. LINDHOLM, M. W., ELMEN, J., FISKER, N., HANSEN, H. F., PERSSON, R., MOLLER, M. R., ROSENBOHM, C., ORUM, H., STRAARUP, E. M., and KOCH, T. (2011). PCSK9 LNA Antisense Oligonucleotides Induce Sustained Reduction of LDL Cholesterol in Nonhuman Primates. Mol. Ther. 20, 376-381.
41. MARTIN, P. (1995). Ein neuer zugang zu 2-O-alkylribonucleosiden und eigenschaften deren oligonucleotiden. Helvetica Chimica Acta 78, 486-504.
42. MAX, K. E., ZEEB, M., BIENERT, R., BALBACH, J., and HEINEMANN, U. (2006). T-rich DNA single strands bind to a preformed site on the bacterial cold shock protein Bs-CspB. J. Mol. Biol. 360, 702-714.
43. MOSCHOS, S. A., FRICK, M., TAYLOR, B., TURNPENNY, P., GRAVES, H., SPINK, K. G., BRADY, K., LAMB, D., COLLINS, D., ROCKEL, T. D., et al. (2011). Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense. Mol. Ther. 19, 2163-2168.
44. MUZET, N., GUILLOT, B., JELSCH, C., HOWARD, E., and LECOMTE, C. (2003). Electrostatic complementarity in an aldose reductase complex from ultra-high-resolution crystallography and first-principles calculations. Proc. Natl. Acad. Sci. U. S. A. 100, 8742-8747.
45. NIELSEN, K. E., SINGH, S. K., WENGEL, J., and JACOBSEN, J. P. (2000). Solution structure of an LNA hybridized to DNA: NMR study of the d(CT(L)GCT(L)T(L)CT(L)GC):d(GCA GAAGCAG) duplex containing four locked nucleotides. Bioconjug. Chem. 11, 228-238.
46. NIELSEN, K. E., and SPIELMANN, H. P. (2005). The structure of a mixed LNA/DNA:RNA duplex is driven by conformational coupling between LNA and deoxyribose residues as determined from (13)C relaxation measurements. J. Am. Chem. Soc. 127, 15273-15282.
47. NIELSEN, P. E., EGHOLM, M., BERG, R. H., and BUCHARDT, O. (1991). Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 254, 1497-1500.
48. OBAD, S., DOS SANTOS, C. O., PETRI, A., HEIDENBLAD, M., BROOM, O., RUSE, C., FU, C., LINDOW, M., STENVANG, J., STRAARUP, E. M., et al. (2011). Silencing of microRNA families by seed-targeting tiny LNAs. Nat. Genet. 43, 371-378.
49. OBIKA, S., NANBU, D., HARI, Y., MORIO, J. A. K., IN, Y., ISHIDA, T., and IMANISHI, T. (1997). Synthesis of 2-0,4-C-methyleneuridine and-cytidine. Novel bicyclic nucleosides having a fixed c3-endo sugar puckering. Tetrahedron Lett. 38, 8735-8738.
50. PETERSEN, M., BONDENSGAARD, K., WENGEL, J., and JACOBSEN, J. P. (2002). Locked nucleic acid (LNA) recognition of RNA: NMR solution structures of LNA:RNA hybrids. J. Am. Chem. Soc. 124, 5974-5982.
51. PETERSEN, M., NIELSEN, C. B., NIELSEN, K. E., JENSEN, G. A., BONDENSGAARD, K., SINGH, S. K., RAJWANSHI, V. K., KOSHKIN, A. A., DAHL, B. M., WENGEL, J., and JACOBSEN, J. P. (2000). The conformations of locked nucleic acids (LNA). J. Mol. Recognit. 13, 44-53.
52. PRAKASH, T. P., MANOHARAN, M., KAWASAKI, A. M., FRASER, A. S., LESNIK, E. A., SIOUFI, N., LEEDS, J. M., TEPLOVA, M., and EGLI, M. (2002). 2-O-[2-(methylthio) ethyl]-modified oligonucleotide: an analogue of 2-O-[2-(methoxy)-ethyl]-modified oligonucleotide with improved protein binding properties and high binding affinity to target RNA. Biochemistry 41, 11642-11648.
53. SETH, P. P., SIWKOWSKI, A., ALLERSON, C. R., VASQUEZ, G., LEE, S., PRAKASH, T. P., WANCEWICZ, E. V., WITCHELL, D., and SWAYZE, E. E. (2009). Short antisense oligonucleotides with novel 2-4 conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J. Med. Chem. 52, 10-13.
54. SHABAROVA, Z. A., Bogdanov, A. A. (1994). Advanced organic chemistry of nucleic acids, (VCH: Weinheim, Germany), pp. 389-471.
55. SHEINERMAN, F. B., NOREL, R., and HONIG, B. (2000). Electrostatic aspects of protein-protein interactions. Curr. Opin. Struct. Biol. 10, 153-159.
56. SINGH, S. K., NIELSEN, P., KOSHKIN, A., and WENGEL, J. (1998). LNA (locked nucleic acids): synthesis and highaffinity nucleic acid recognition. Chem. Commun. 455-456.
57. SOIFER, H. S., KOCH, T., LAI, J., HANSEN, B., HOEG, A., OERUM, H., and STEIN, C. A. (2012). Silencing of gene expression by gymnotic delivery of antisense oligonucleotides. Methods Mol. Biol. 815, 333-346.
58. STANTON, R., SCIABOLA, S., SALATTO, C., WENG, Y., MOSHINSKY, D., LITTLE, J., WALTERS, E., KREEGER, J., DIMATTIA, D., CHEN, T., et al. (2012). Chemical modification study of antisense gapmers. Nucleic Acid Ther. 22, 344-359.
59. STEIN, C. A., HANSEN, J. B., LAI, J., WU, S., VOSKRESENSKIY, A., HOG, A., WORM, J., HEDTJARN, M., SOULEIMANIAN, N., MILLER, P., SOIFER, H. S., et al. (2010). Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res. 38, e3.
60. STEIN, C. A., WU, S., VOSKRESENSKIY, A. M., ZHOU, J. F., SHIN, J., MILLER, P., SOULEIMANIAN, N., and BENIMETSKAYA, L. (2009). G3139, an anti-Bcl-2 antisense oligomer that binds heparin-binding growth factors and collagen I, alters in vitro endothelial cell growth and tubular morphogenesis. Clin. Cancer Res. 15, 2797-2807.
61. STRAARUP, E. M., FISKER, N., HEDTJARN, M., LINDHOLM, M. W., ROSENBOHM, C., AARUP, V., HANSEN, H. F., ORUM, H., HANSEN, J. B., and KOCH, T. (2010). Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res. 38, 7100-7111.
62. SULEA, T., and PURISIMA, E. O. (2003). Profiling charge complementarity and selectivity for binding at the protein surface. Biophys. J. 84, 2883-2896.
63. SUN, S., and SHAMOO, Y. (2003). Biochemical characterization of interactions between DNA polymerase and singlestranded DNA-binding protein in bacteriophage RB69. J. Biol. Chem. 278, 3876-3881.
64. TRAPANE, T., and TS'O, P. (1994). Triplex formation at single-stranded nucleic acid target sites of unrestricted sequences by two added strands of oligonucleotides: a proposed model. J. Am. Chem. Soc. 116, 10437-10449.
65. UHLMANN, E. (2000). Recent advances in the medicinal chemistry of antisense oligonucleotides. Curr. Opin. Drug Discov. Devel. 3, 203-213.
66. UHLMANN, E., and PEYMAN, A. (1990). Antisense oligonucleotides: a new therapeutic principle. Chem. Rev. 90, 544-579.
67. WAHLESTEDT, C., SALMI, P., GOOD, L., KELA, J., JOHNSSON, T., HOKFELT, T., BROBERGER, C., PORRECA, F., LAI, J., REN, K., et al. (2000). Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl. Acad. Sci. U. S. A 97, 5633-5638.
68. WATANABE, T. A., GEARY, R. S., and LEVIN, A. A. (2006). Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides 16, 169-180.
69. WATSON, J. D., and CRICK, F. H. C. (1953a). A structure of deoxyribose nucleic acid. Nature 171, 737-738.
70. WATSON, J. D., and CRICK, F. H. C. (1953b). Genetical implications of the structure of deoxyribonucleic acid. Nature 171, 964-967.
71. WENGEL, J. (2001). LNA (locked nucleic acid). In: Antisense Drug Technology; Principles, Strategies, and Applications. S. T. Crooke, ed. (Marcel Dekker: New York), pp. 339-357.
72. YAMAMOTO, T., NAKATANI, M., NARUKAWA, K., and OBIKA, S. (2011). Antisense drug discovery and development. Future Med. Chem. 3, 339-365.
73. ZAMECNIK, P. C., and STEPHENSON, M. L. (1978). Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligonucleotide. Proc. Natl. Acad. Sci. U. S. A. 75, 280-284.
74. ZEEB, M., MAX, K. E., WEININGER, U., LOW, C., STICHT, H., and BALBACH, J. (2006). Recognition of T-rich singlestranded DNA by the cold shock protein Bs-CspB in solution. Nucleic Acids Res. 34, 4561-4571.